Divergent requirements for the MAPK(ERK) signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein-Barr virus latency by phorbol esters

Journal of Virology

Volumn 73, Issue 10, 1999, Pages 8913-8916

  Fenton, Mandy ^a   Sinclair, Alison J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL ESTER;

ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS LATENCY;

EID: 0032824656     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.10.8913-8916.1999     Document Type: Article

References (27)

1. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 46:27489-27494.
2. Clarke, E. A., and J. A. Ledbetter. 1986. Activation of human B cells mediated through two distinct cell surface differentiation antigens Bp35 and Bp50. Proc. Natl. Acad. Sci. USA 83:4494-4497.
3. Cohen, P. 1997. The search for physiological substrates for MAP and SAP kinases in mammalian cells. Trends Cell Biol. 7:353-361.
4. Davies, A. H., R. Grand, F. J. Evans, and A. B. Rickinson. 1991. Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein-kinase-C. J. Virol. 65:6838-6844.
5. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686-7689.
6. Eliopoulos, A. G., S. Blake, J. E. Floettmann, M. Rowe, and L. S. Young. 1999. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1023-1035.
7. Eliopoulos, A. G., and A. B. Rickinson. 1998. Epstein-Barr virus: LMP1 masquerades as an active receptor. Curr. Biol. 8:R196-R198.
8. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the c-jun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
9. Fenton, M., N. Bone, and A. J. Sinclair. 1998. The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line. J. Immunol. Methods 212:41-48.
10. Gordon, J., M. J. Millsum, L. Flores-Rymo, and S. Gillis. 1989. Regulation of resting and cycling human B lymphocytes via surface IgM and the accessory molecules interleukin-4, CD23 and CD40. Immunology 68:526-531.
11. Hatzivassillou, E., W. E. Miller, N. Raab Traub, E. Kieff, and G. Mosialos. 1998. Fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160: 1116-1121.
12. Hollyoake, M., A. Stuhler, P. Farrell, J. Gordon, and A. J. Sinclair. 1995. The normal cell cycle activation program is exploited during the infection of quiescent primary B-lymphocytes by Epstein-Barr virus. Cancer Res. 55: 4784-4787.
13. Hunter, T. 1997. Oncoprotein networks. Cell 88:333-346.
14. Kleser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478-6485.
15. King, W., A. L. Thomas-Powell, N. Raab-Traub, M. Hawke, and E. Kieff. 1980. Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J. Virol. 36:506-518.
16. Nishizuka, Y. 1988. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661-665.
17. Nishizuka, Y. 1984. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308:693-698.
18. Rickinson, A., and E. Keiff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Field's virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
19. Roberts, M. L., and N. R. Cooper. 1998. Activation of a Ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 240:93-99.
20. Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:180-186.
21. Sinclair, A. J., and P. J. Farrell. 1992. Epstein-Barr virus transcription factors. Cell Growth Differ. 3:557-563.
22. Sinclair, A. J., and P. J. Farrell. 1995. Methods to study Epstein-Barr virus and p53 status in human cells, p. 89-100. In K. W. Aldolph (ed.), Methods in molecular genetics, vol. 7. Academic Press, Orlando, Fla.
23. Sinclair, A. J., M. Fenton, and D. Delikat. 1998. Interactions between EBV and the cell cycle control machinery. Histol. Histopathol. 13:461-467.
24. Sinclair, A. J., I. Palmero, G. Peters, and P. J. Farrell. 1994. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
25. Speck, S. H., T. Chatila, and E. Flemmington. 1997. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5:399-405.
26. Widmann, C., S. Gibson, M. B. Jarpe, and G. L. Johnson. 1999. Mitogen activated protein kinase: conservation of a three kinase module from yeast to human. Physiol. Rev. 79:143-180.
27. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced by tumour promoter TPA. Nature 272:373-375.